Molecular Subtypes Based on Cell Differentiation Trajectories in Head and Neck Squamous Cell Carcinoma: Differential Prognosis and Immunotherapeutic Responses

Abstract

ObjectiveHead and neck squamous cell carcinoma (HNSCC) is one of the most common and lethal malignant tumors. We aimed to investigate the HNSCC cell differentiation trajectories and the corresponding clinical relevance.MethodsBased on HNSCC cell differentiation-related genes (HDRGs) identified by single-cell sequencing analysis, the molecular subtypes and corresponding immunity, metabolism, and stemness characteristics of 866 HNSCC cases were comprehensively analyzed. Machine-learning strategies were used to develop a HNSCC cell differentiation score (HCDscore) in order to quantify the unique heterogeneity of individual samples. We also assessed the prognostic value and biological characteristics of HCDscore using the multi-omics data.ResultsHNSCCs were stratified into three distinct molecular subtypes based on HDRGs: active stroma (Cluster-A), active metabolism (Cluster-B), and active immune (Cluster-C) types. The three molecular subtypes had different characteristics in terms of biological phenotype, genome and epigenetics, prognosis, immunotherapy and chemotherapy responses. We then demonstrated the correlations between HCDscore and the immune microenvironment, subtypes, carcinogenic biological processes, genetic variation, and prognosis. The low-HCDscore group was characterized by activation of immunity, enhanced response to anti-PD-1/PD-L1 immunotherapy, and better survival compared to the high-HCDscore group. Finally, by integrating the HCDscore with prognostic clinicopathological characteristics, a nomogram with strong predictive performance and high accuracy was constructed.ConclusionsThis study revealed that the cell differentiation trajectories in HNSCC played a nonnegligible role in patient prognosis, biological characteristics, and immune responses. Evaluating cancer cell differentiation will help to develop more effective immunotherapy, metabolic therapy, and chemotherapy strategies.

Enhancing immunotherapy outcomes by targeted remodeling of the tumor microenvironment via combined cGAS-STING pathway strategies

“…Based on the spatial distribution of CD8 + cytotoxic T lymphocytes (CTLs) within the TME, tumors have been categorized into three primary immune phenotypes: immune-inflamed, immune-excluded, and immune-desert ( 7 , 8 ). In immune-inflamed tumors, CD8 + T cells penetrate the tumor parenchyma, whereas in immune-excluded tumors, they gather around the tumor parenchyma without infiltrating it, and are completely absent in immune-desert tumors and their peripheries ( 9 , 10 ). Immune-inflamed tumors, termed “hot” tumors, demonstrate a notable response to treatment with immune checkpoint inhibitors (ICIs) ( 11 , 12 ), characterized by significant T cell infiltration, increased inflammatory signaling (notably interferon-γ), heightened PD-L1 expression, and a substantial mutational burden ( 11 , 13 ).…”

Cuprotosis Programmed-Cell-Death-Related lncRNA Signature Predicts Prognosis and Immune Landscape in PAAD Patients

“…Different clinical features and treatment outcomes might occur in patients with the same clinical stage, suggesting that the prognosis of tumors based on traditional clinical indicators is not entirely accurate. Traditional prognostic indicators include the TNM stage, pathological grade, and histological grade [ 7 ]. Patients’ clinical stages determine the chemotherapy and immunotherapy strategies.…”